AI assistant
Sending…
PMV Pharmaceuticals, Inc. — Director's Dealing 2023
Sep 18, 2023
34350_dirs_2023-09-18_2749ae65-e5d9-4182-bbc1-089f834ec98b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2023-09-15
Reporting Person: Alland Leila (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-09-15 | Common Stock | S | 6291 | $6.62 | Disposed | 45909 | Direct |
Footnotes
F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.
More from PMV Pharmaceuticals, Inc.
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Annual Report
2026
Apr 22
Proxy Solicitation & Information Statement
2026
Apr 22
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 9
Interim / Quarterly Report
2025
Nov 12
Regulatory Filings
2025
Nov 12
Major Shareholding Notification
2025
Nov 12
Director's Dealing
2025
Oct 29